NeoRecormon (epoetin beta; Roche/Chugai) Drug Analysis Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: NeoRecormon" drug pipelines has been added to ResearchAndMarkets.com's offering.

NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD). The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow (EMC, 2017). NeoRecormon is comparable to Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) in terms of its clinical profile, with similar safety, efficacy, and dosing.

Key Topics Covered:

Product Profiles

NeoRecormon: Anemia in chronic kidney disease

List of Figures

Figure 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24

List of Tables

Table 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vdgpqh/neorecormon?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs